Article Text

Download PDFPDF
Benefits of early intensive glucose control to prevent diabetes complications were sustained for up to 10 years

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

R R Holman

Dr R R Holman, Diabetic Trials Unit, Oxford, UK;



randomised controlled trial (UK Prospective Diabetes Study [UKPDS]). Current Controlled Trials ISRCTN75451837.




blinded (outcome adjudication committee).†



23 centres in the UK.


4209 patients 25–65 years of age {mean age 53 y, 60% men}* who had newly diagnosed type 2 diabetes and fasting plasma glucose concentrations >6.0 mmol/l (108 mg/dl) and <15.0 mmol/l (270 mg/dl) after 3 months of dietary therapy. Exclusion criteria included recent myocardial infarction, current angina or heart failure, and >1 major vascular event.


intensive glucose control with a sulfonylurea or insulin (n = 2729) or conventional therapy with diet (n = 1138). Overweight patients were also allocated to a third group involving intensive therapy with metformin (n = 342).


7 composite outcomes (any diabetes-related end point, diabetes-related death, death from any cause, myocardial infarction, stroke, peripheral vascular disease, and microvascular disease).

Follow-up period:

median 9 years after the end of the trial, 17 years total.

Patient follow-up:

80–97% (intention-to-treat analysis). …

View Full Text


  • Source of funding: UK Medical Research Council; UK Department of Health; Diabetes UK; British Heart Foundation; UK National Institute for Health; 6 drug companies.